Patient Support

Offer potential to improve patient care, including in medication adherence.

Choosing the right pharmacy to administer the program involves a number of factors.

The importance of industry, as it moves forward, in focusing on patient-centered care and prioritizing patient needs across the supply chain.

Agreement is expected to help improve the medication delivery process for patients.

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Company delivers additional supply chain logistics and distribution experience to specialty pharmaceutical market.

The platform agnostic CGT hub hopes to streamline the path-to-care process, by providing physicians and patient services teams with visibility across the therapy development and delivery process.

Although there is no ‘one size fits all’ solution, the process is influenced by factors such as lifestyle stage, competitive outlook, and market constraints.

Innovation and investment in advancing lifesaving therapies for pediatric patients to the commercial stage remains a daunting task, but rapid advances today in modeling and simulation are reducing the hurdles for drugmakers.

With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.

Deciphering the different "technology-first” and “technology-enabled” patient support programs.

How personalized interventions can help boost the omnichannel experience for patient hubs—and drive engagement and impact adherence in outcomes.

Pharma Commerce offers a synopsis of some of the conference’s events.

Pharma Commerce provides a look into a few of the conference’s highlights.

Jessica Longo offers her insights on the changing patient access landscape.

Novo Nordisk executive dives into supporting cardiometabolic patients within her current role.

VP for TrialCard talks steps to making PAP processes more efficient.

Diana Villanova explains the knowledge obtained by attendees from her breakout session.

TrialCard exec describes how her experience in biotech consulting led to her current position.

TrialCard VP offers a synopsis of breakout session.

Corey Ford comments on his second PAP presentation, with this one centered around broadening the definition of adherence.

AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles.

Corey Ford dives into questions brought up during his 'state of the union' presentation.

AmerisourceBergen exec highlights his 'state of the industry' address that he made at day one of the conference.

With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

As the range of treatment options for rheumatoid arthritis (RA) continues to grow and biosimilars are poised to enter the arena, the need for expert strategies to improve therapy selection and address the access, affordability, and adherence challenges patients face is coming into sharper focus.

How artificial intelligence and real-world data has not just helped predict patient behavior, but has also been successful at the point-of-care for life sciences companies.  

How biopharma commercial teams can leverage machine learning techniques to improve targeting of HCPs and patients

How privacy and technology literacy can coexist behind a blockchain-based approach to patient data analytics and control

How artificial intelligence is improving the patient experience